AR070460A1 - Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen - Google Patents

Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen

Info

Publication number
AR070460A1
AR070460A1 ARP090100604A ARP090100604A AR070460A1 AR 070460 A1 AR070460 A1 AR 070460A1 AR P090100604 A ARP090100604 A AR P090100604A AR P090100604 A ARP090100604 A AR P090100604A AR 070460 A1 AR070460 A1 AR 070460A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
group
independently selected
triazolyl
Prior art date
Application number
ARP090100604A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR070460A1 publication Critical patent/AR070460A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP090100604A 2008-02-21 2009-02-20 Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen AR070460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
AR070460A1 true AR070460A1 (es) 2010-04-07

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100604A AR070460A1 (es) 2008-02-21 2009-02-20 Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen

Country Status (23)

Country Link
US (1) US8716483B2 (enExample)
EP (1) EP2260031B1 (enExample)
JP (1) JP5276676B2 (enExample)
KR (1) KR20100117123A (enExample)
CN (1) CN102015693B (enExample)
AR (1) AR070460A1 (enExample)
AU (1) AU2009215534B8 (enExample)
BR (1) BRPI0908120A8 (enExample)
CA (1) CA2714479A1 (enExample)
CL (1) CL2009000394A1 (enExample)
CO (1) CO6300939A2 (enExample)
EC (1) ECSP10010415A (enExample)
ES (1) ES2556353T3 (enExample)
IL (1) IL207530A (enExample)
MX (1) MX2010009268A (enExample)
MY (1) MY152271A (enExample)
NZ (1) NZ587504A (enExample)
PE (1) PE20091491A1 (enExample)
RU (1) RU2525389C2 (enExample)
SG (1) SG188179A1 (enExample)
TW (1) TWI398441B (enExample)
WO (1) WO2009105500A1 (enExample)
ZA (2) ZA201005909B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
EP2316031B1 (en) * 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
EP2584903B1 (en) * 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
AU2011329067A1 (en) * 2010-11-16 2013-05-30 Medimmune, Llc Regimens for treatments using anti-IGF antibodies
US9000209B2 (en) 2011-07-22 2015-04-07 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
PL2820009T3 (pl) 2012-03-01 2018-09-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
RU2701156C9 (ru) 2012-07-18 2019-12-18 Саншайн Лейк Фарма Ко., Лтд. Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2900241B1 (en) * 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2897618A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
PT3052096T (pt) 2013-10-03 2018-04-04 Kura Oncology Inc Inibidores de erk e métodos de utilização
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
BR112017012547A2 (pt) * 2014-12-18 2018-03-13 Merck Sharp & Dohme Corp. Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
BR112017012558A2 (pt) * 2014-12-19 2018-01-02 Merck Sharp & Dohme Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
HRP20200805T1 (hr) 2015-04-03 2020-10-16 Recurium Ip Holdings, Llc Spirociklički spojevi
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
CN114867529B (zh) 2019-10-09 2024-09-27 拜耳公司 作为农药的新的杂芳基三唑化合物
JP7326622B2 (ja) 2019-12-06 2023-08-15 メッドシャイン ディスカバリー インコーポレイテッド Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997045412A1 (en) 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
CA2369504C (en) 2000-02-05 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CA2369502A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002022610A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
EP1318814B1 (en) 2000-09-15 2007-05-30 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
CA2429258A1 (en) 2000-11-20 2002-06-13 Scios Inc. Piperidine/piperazine-type inhibitors of p38 kinase
US7625913B2 (en) 2000-12-21 2009-12-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
KR20040007497A (ko) 2001-04-16 2004-01-24 에자이 가부시키가이샤 신규 1ｈ-인다졸 화합물
US6962936B2 (en) 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
EP1461334A2 (en) 2001-04-27 2004-09-29 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CA2456187A1 (en) 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
WO2003011855A2 (en) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US7253199B2 (en) 2001-10-23 2007-08-07 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
WO2004083203A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2004293035A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
EP1715871A1 (en) 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
JP2007532615A (ja) 2004-04-13 2007-11-15 アステックス、セラピューティックス、リミテッド 医薬化合物
BRPI0511124A (pt) 2004-05-14 2007-11-27 Vertex Pharma pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
DK3305776T3 (da) 2004-05-14 2019-12-09 Vertex Pharma Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
EP1833820A1 (en) 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinase and uses therof
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
HRP20110892T1 (hr) * 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
EP2018872A4 (en) 2006-04-20 2010-06-09 Takeda Pharmaceutical PHARMACEUTICAL PRODUCT
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
US7884107B2 (en) 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
EP2560007A1 (en) 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
AU2008262412A1 (en) * 2007-06-05 2008-12-18 Merck Sharp & Dohme Corp. Polycyclic indazole derivatives and their use as ERK inhibitors for the treatment of cancer
KR20100032886A (ko) 2007-06-08 2010-03-26 아보트 러보러터리즈 키나제 억제제로서의 5-헤테로아릴 치환된 인다졸
MX2009014208A (es) 2007-06-18 2010-01-28 Schering Corp Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物

Also Published As

Publication number Publication date
ES2556353T3 (es) 2016-01-15
TWI398441B (zh) 2013-06-11
AU2009215534B8 (en) 2014-07-10
CN102015693B (zh) 2014-10-29
BRPI0908120A8 (pt) 2017-10-24
CN102015693A (zh) 2011-04-13
MY152271A (en) 2014-09-15
JP5276676B2 (ja) 2013-08-28
ZA201005909B (en) 2014-03-26
EP2260031B1 (en) 2015-10-07
MX2010009268A (es) 2010-09-14
EP2260031A1 (en) 2010-12-15
AU2009215534A2 (en) 2010-12-23
TW200948799A (en) 2009-12-01
US20110189192A1 (en) 2011-08-04
CL2009000394A1 (es) 2011-02-11
WO2009105500A1 (en) 2009-08-27
US8716483B2 (en) 2014-05-06
KR20100117123A (ko) 2010-11-02
PE20091491A1 (es) 2009-09-25
AU2009215534A8 (en) 2014-07-10
AU2009215534A1 (en) 2009-08-27
ES2556353T8 (es) 2017-10-13
ECSP10010415A (es) 2010-09-30
IL207530A (en) 2014-08-31
RU2010138635A (ru) 2012-03-27
ZA201400396B (en) 2014-12-23
SG188179A1 (en) 2013-03-28
CA2714479A1 (en) 2009-08-27
BRPI0908120A2 (enExample) 2017-08-22
RU2525389C2 (ru) 2014-08-10
AU2009215534B2 (en) 2014-06-26
CO6300939A2 (es) 2011-07-21
NZ587504A (en) 2012-09-28
IL207530A0 (en) 2010-12-30
JP2011513225A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
AR070460A1 (es) Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen
BRPI0717767A2 (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase
IN2014DN07283A (enExample)
IL198116A0 (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008007123A3 (en) Pharmaceutical compounds
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
AR057911A1 (es) Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
MX2010006421A (es) Compuestos organicos.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
SMT201300085B (it) Composti di pirrolo
AR067105A1 (es) Moleculas pequenas que contienen boro
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
BRPI0812942A8 (pt) Composto derivado de 3-amino-6 - (1-amino-etil) - tetra-hidropirano, composição farmacêutica e uso de referido composto.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
NZ586650A (en) Inhibitors of iap
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.
PH12015502851A1 (en) Curable composition
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica
RU2011108359A (ru) Фармацевтическая композиция, содержащая производное 1,2-дитиолтиона, для предотвращения или лечения заболевания, обусловленного повышенной экспрессией lxr-альфа

Legal Events

Date Code Title Description
FG Grant, registration